Kairos Pharma, LTD.
KAPA NYSE
SEC CIK 1962011
Follow Kairos Pharma, LTD.
Weekly email: filings, results
Net income
−$2M
−41.9% vs same quarter last year
EPS, diluted
−$0.59
−22.9% vs same quarter last year
Operating cash flow
−$979K
−16.8% vs same quarter last year
Operating income
−$2M
−40% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$5.4M |
| FY24 | −$2.6M |
| FY23 | −$1.8M |
| FY22 | - |